Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels (NCT06496243)
A Phase 2 Study to Evaluate the Effect of Obicetrapib Alone and in Combination With Evolocumab (Repatha®) on Lipoprotein (a) in Patients With Mild Dyslipidemia: The VINCENT Study
🩺 Plain-English Summary (8th-Grade Level)
The goal of this open label 16 week trial is to evaluate Lp(a) levels for patients with elevated Lp(a) being treated with obicetrapib and obiceptrapib/evolocumab Patients will: Have baseline Lp(a) tested at randomization Take 10mg/dL obiceptrapib daily for 8 weeks and have Lp(a) tested at Week 8 Take 10 mg/dL obicetrapib daily/evolocumab 140 every other week for 8 weeks and have Lp(a) retested at Week 16
Who can join: Review the eligibility criteria below.
Location: UPenn — Philadelphia, Pennsylvania
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- UPenn — Philadelphia, Pennsylvania
📞 Contact the Study Coordinator
Phone: (919) 641-5724
Email: ashley.walker@newamsterdampharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Dyslipidemias
- Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity — Storrs, Connecticut
- Meta-analyses of Soy Protein and Its Food Sources for Cholesterol Reduction — Toronto, Ontario
- Lipid Testing After Myocardial Infarction at the Montreal Heart Institute — Montreal, Quebec
- Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial) — Los Angeles, California
- Group Medical Visits for Patients With Dyslipidemia — Dieppe, New Brunswick
Explore by condition: All Dyslipidemias clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.